TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00409253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: URAPIDIL (EUPRESSYL*)
Description: Urapidil (Eupressyl\*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NICARDIPINE
Description: Nicardipine : IV 6.25 mg bolus until PAD \>105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days
Study: NCT01188473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NPPV plus standard of care
Description: Patients in the NPPV group were fitted with a nasal mask with gel seals (Comfortgel Masks, Respironics) and placed on the BiPAP Machine (Vision Bipap, Respironics). To optimize patient cooperation, the mask was initially applied manually to the patient's face. After a short adaptation period, it was firmly applied on the face by head straps to minimize air leak without causing skin injury. Pressures were initially set low for comfort and acceptance while being placed on the machine. The inspiratory positive airway pressure (IPAP) was gradually increased to 8 cm H2O in order to achieve a tidal volume of 6-9 ml/kg and the end expiratory positive airway pressure (EPAP) to 5 cm H 2O. These settings remained unchanged throughout the study period.
Study: NCT05044026

Intervention type: OTHER
Intervention: Jakavi
Description: Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.

Intervention type: OTHER
Intervention: Jakavi
Description: Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
Study: NCT01287364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclesonide hydrofluoroalkane (HFA) nasal aerosol
Description: ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclesonide hydrofluoroalkane (HFA) nasal aerosol
Description: ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone nasal inhalation
Description: mometasone nasal inhalation 200 μg once daily for one week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone nasal inhalation
Description: mometasone nasal inhalation 200 μg once daily for one week
Study: NCT00593749

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Corner Store Initiative
Description: modification of snacks and beverages offered in corner store surrounding 10 schools

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: control group in study
Study: NCT04092062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ToothWave
Description: RF-utilizing powered toothbrush for teeth whitening

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: powered toothbrush
Description: regular powered toothbrush with no RF
Study: NCT01603082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180 mg loading dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600 mg loading dose
Study: NCT03570853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-3RP
Description: This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology). The program consists of 8, 1.5 hour sessions.
Study: NCT02616523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The participants will be given infusion of normal saline intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
Study: NCT04359251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gas exchanges at different PEEP
Description: Gas exchanges measurement at different PEEP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung mechanics at different PEEP
Description: lung mechanics measurement at different PEEP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamics changes at different PEEP
Description: Hemodynamics changes measurement at different PEEP
Study: NCT02187809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam
Study: NCT03347721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine gel
Description: 2% lidocaine jelly, injected into the urethra
Study: NCT03037619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit+Support
Description: Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months.
Study: NCT02329665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeedleWays™ System
Description: A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
Study: NCT03030235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Oral Tablet
Description: Dapagliflozin 10Mg Oral Tablet
Study: NCT03347721

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lubricant Gel
Description: Lubricating gel
Study: NCT04495244

Intervention type: DIAGNOSTIC_TEST
Intervention: Syantra DX Breast Cancer
Description: Blood test for detecting the presence of breast cancer.
Study: NCT03030235

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin matching placebo
Description: Dapagliflozin matching placebo
Study: NCT02941133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization
Description: Neural mobilization techniques aimed at the lumbar root that is affected

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Ultrasound - Transcutaneous electrical nerve stimulation (TENS) - Massage therapy - Strengthening exercises
Study: NCT00443638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse home visitation
Description: Nurse home visitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse home visitation
Description: Nurse home visitation
Study: NCT04932538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kİnesio Taping
Description: Kinesio Taping® (KT) is used for pediatric rehabilitation to reduce pain, facilitate or inhibit muscle activity, prevent injuries, reposition joints, aid the lymphatic system, support postural alignment, and improve proprioception
Study: NCT03193489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-treatment control
Description: After 3 weeks of intensive treatment, no special exercises are performed as a control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Parkinson group
Description: No treatment.
Study: NCT01050686

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: insertion of subcutaneous wound drain
Description: after the abdominal fascia is closed and before skin closure, a subcutaneous wound drain is inserted

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no insertion of subcutaneous wound drain
Description: closure of abdominal wall and skin without insertion of subcutaneous wound drain
Study: NCT02927587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The induction Cet of propofol
Description: The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.

Intervention type: DRUG
Group type: OTHER
Intervention: The induction Cet of propofol
Description: The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.
Study: NCT04646070

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction mammaplasty
Description: Breast reduction surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction mammaplasty
Description: Breast reduction surgery
Study: NCT02366013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rcAd26.MOS1.HIV-Env 1x10^8 vp
Description: 1 oral capsule, 1x10\^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rcAd26.MOS1.HIV-Env 1x10^9 vp
Description: 10 oral capsules, 1x10\^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rcAd26.MOS1.HIV-Env 1x10^10 vp
Description: 1 oral capsule, 1x10\^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rcAd26.MOS1.HIV-Env 1x10^11 vp
Description: 10 oral capsules, 1x10\^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
Study: NCT04669977

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry juice
Description: One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. Also, a reminder of the next clinical visit is attached. They are expected to finish the mulberry juice in 10 to 11days instead of 12 days.
Study: NCT01717768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.
Study: NCT03750383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Day 1 and Day 5 (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive one dose of EDP-938 on Day 1 and Day 8 (Part 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Subjects will receive one dose of cyclosporine on Day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Subjects will receive prednisone once daily from Day 5 to Day 14
Study: NCT00827762

Intervention type: DRUG
Intervention: Kuvan
Description: 20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Study: NCT01032382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
Description: topical application to CL lesions once daily for 20 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paromomycin Alone Cream (15% paromomycin topical cream)
Description: topical application to CL lesions once daily for 20 days
Study: NCT04553068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVO100
Description: EVO100 vaginal gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal gel
Study: NCT04410250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral hygiene
Description: Mothers will be instructed on the oral hygiene of the newborn

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: oral hygiene
Description: Mothers will be instructed on the oral hygiene of the newborn
Study: NCT01922479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: 1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
Study: NCT01723813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor specific peptides: MAGE-3.A1 and / or NA17.A2
Description: Each peptide will be given at a dose of 300 µg in 1 ml of sodium chloride 0.9%, every 3 weeks on 6 occasions, and will be administered at one site in arm or thigh, 20% of the dose intradermally and 80% of the dose subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor specific peptides: MAGE-3.A1 and / or NA17.A2
Description: Each peptide will be given at a dose of 300 µg in 1 ml of sodium chloride 0.9%, every 3 weeks on 6 occasions, and will be administered at one site in arm or thigh, 20% of the dose intradermally and 80% of the dose subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galectin-3 inhibitor: GM-CT-01 systemic injections
Description: Systemic injection of GM-CT-01: GM-CT-01 will be administered by slow intravenous infusions at a dose of 280 mg/m2, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galectin-3 inhibitor: GM-CT-01 systemic injections
Description: Systemic injection of GM-CT-01: GM-CT-01 will be administered by slow intravenous infusions at a dose of 280 mg/m2, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration
Description: GM-CT-01 will be injected peri-tumoral at a dose of 100 µg per tumor injected, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination. If a patient has one or two superficial metastases at day 43 of the treatment, one of these lesions will be treated. If a patient has more than two superficial metastases at day 43, two of these lesions will be treated.
Study: NCT01881581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution is used as control in all arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution is used as control in all arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution is used as control in all arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution is used as control in all arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution is used as control in all arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution is used as control in all arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution is used as control in all arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution is used as control in all arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-GPEi
Description: D-GPEi is used in Arm A,B,C,G and H.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-GPEi
Description: D-GPEi is used in Arm A,B,C,G and H.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-GPEi
Description: D-GPEi is used in Arm A,B,C,G and H.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-GPEi
Description: D-GPEi is used in Arm A,B,C,G and H.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-GPEi
Description: D-GPEi is used in Arm A,B,C,G and H.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-GPE
Description: M-GPE is used in Arm D,E,F,G and H

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-GPE
Description: M-GPE is used in Arm D,E,F,G and H

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-GPE
Description: M-GPE is used in Arm D,E,F,G and H

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-GPE
Description: M-GPE is used in Arm D,E,F,G and H

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-GPE
Description: M-GPE is used in Arm D,E,F,G and H
Study: NCT00937833

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis Male Sling
Study: NCT03099317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sinew acupuncture
Description: Sinew acupuncture: subject will sit on chair with knee joint flexion with a most comfortable angle nearest to 90 degrees. Acupoints (1-2cm away from the point of tenderness or pain) near the knee will be punctured through the skin by using sterile needles of size 0.30mm × 40mm at the angle of 0-10 degrees pointing along the pain direction and meridian sinew. Immediately, needles will be retreated back just under the skin and inserted 10mm-20mm forward smoothly with minimal pain sensation. Walking and stepping will be advised and governed during acupuncture. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject. The treatment will last 20 minutes for each session.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture: subject will receive the same procedures as the sinew acupuncture without penetrating the skin. The needle will be used to puncture on the acupoint slightly without passing through the skin. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject.
Study: NCT01822522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04495244

Intervention type: DIAGNOSTIC_TEST
Intervention: Syantra DX Breast Cancer
Description: Blood test for detecting the presence of breast cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Syantra DX Breast Cancer
Description: Blood test for detecting the presence of breast cancer.
Study: NCT01822522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01629784

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cutaneous Lupus educational script
Description: Subjects will listen to a short informational script on Cutaneous lupus and skin protection
Study: NCT01292798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally